GLP-3 (Triple-G)

GLP-3 (Triple-G) is an injectable research peptide cataloged in the Weight Loss & Metabolic category as a single-molecule, multi-receptor incretin analog. As the "Triple-G" designation suggests, it is structured to engage three gut-hormone signaling pathways concurrently — the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor systems — distinguishing it within the catalog from single- and dual-agonist peptides (GLP-1 and GLP-2). It is supplied as a lyophilized powder for reconstitution and is intended strictly for laboratory research and professional reference use by licensed practitioners. This compound is not approved by the FDA for therapeutic use and is not offered for the diagnosis, treatment, cure, or prevention of any condition.

Within the scientific literature, tri-agonist incretin peptides of this class are an active area of investigation in metabolic, endocrine, and energy-homeostasis research. The material in this listing is provided to qualified institutions and licensed ordering providers as a research reference only; any application is determined independently by the receiving practitioner, and individual results vary.

• Investigated in preclinical and metabolic research literature for its activity at multiple incretin receptor targets (GLP-1, GIP, and glucagon); individual results vary
• Studied in research models for effects on energy balance, appetite-related signaling, and body-weight regulation; individual results vary
• Examined in the literature for influence on glucose homeostasis and insulin secretion under glucose-dependent conditions; individual results vary
• Investigated in research contexts for markers of lipid metabolism and hepatic energy handling; individual results vary
• Used as a reference comparator in studies of single- versus dual- versus tri-receptor incretin agonism

Reference handling information only. The lyophilized peptide is typically reconstituted with bacteriostatic water (or another sterile diluent selected by the laboratory) introduced slowly against the vial wall, then swirled gently rather than shaken to help preserve peptide integrity. Sealed lyophilized vials are generally stored refrigerated at approximately 2-8°C; for extended storage, freezing of the unreconstituted powder is commonly referenced. Reconstituted material is generally kept refrigerated, protected from light, and used within a short working window per standard laboratory practice. Protect from heat, light, repeated freeze-thaw cycles, and prolonged room-temperature exposure, and confirm vial integrity before use. All clinical protocols, reconstitution parameters, and handling decisions are determined solely by the licensed ordering provider; this is reference information for research and professional use only and is not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

In the published research rationale for tri-agonist incretin peptides, a single molecule is engineered to bind and activate three distinct receptors — GLP-1, GIP, and glucagon — that together participate in the gut-brain-pancreas axis governing energy homeostasis. GLP-1 receptor engagement is studied for glucose-dependent insulinotropic signaling and satiety-related pathways; GIP receptor activity is investigated for its complementary effects on insulin response and adipose handling; and glucagon receptor activation is examined in the literature for its proposed contribution to energy expenditure and hepatic substrate metabolism. The proposed concept is that simultaneous, balanced activity across all three pathways may produce additive or synergistic metabolic signaling relative to single- or dual-receptor approaches. These mechanisms are described as studied or proposed in research settings only; outcomes are not established and individual results vary.